The research comes at a pivotal moment for cardiovascular medicine. Clinical trials of HDL-raising drugs have repeatedly failed to deliver the promised reduction in heart attacks and strokes, forcing scientists to reconsider whether the quantity of HDL in the blood is the right thing to measure at all. Attention has shifted to HDL quality, the idea that some HDL particles perform their protective functions well while others may be dysfunctional or even harmful. The new study provides some of the most detailed mechanistic evidence to date that a specific, identifiable HDL subtype can be pro-atherogenic, and it argues that targeting HDL quality, rather than simply raising HDL cholesterol numbers, could open a genuinely new therapeutic front against atherosclerotic cardiovascular disease.

To isolate the culprit, the researchers turned to anion-exchange chromatography, a technique that separates lipoproteins according to their surface electrical charge. HDL from human plasma can be resolved into five fractions, designated H1 through H5, with H5 being the most electronegative, meaning it carries an unusually strong negative surface charge that reflects underlying biochemical alterations. The team applied this method to blood samples from 131 asymptomatic individuals, 95 of whom had metabolic syndrome and 36 of whom served as healthy controls. The results were striking: plasma H5 levels were significantly elevated in those with cardiovascular disease risk, averaging 4.0 percent of total HDL compared with 2.7 percent in controls, a difference that reached statistical significance.

The clinical implications became clearer when the researchers examined an imaging cohort of 118 participants who underwent carotid ultrasound assessments. Elevated H5 levels were independently associated with structural markers of subclinical atherosclerosis, including increased intima-media thickness, a measure of the thickening of the inner two layers of the carotid artery wall, and greater plaque burden. These associations held after accounting for conventional risk factors, suggesting that H5 is not merely a passive bystander in metabolic disease but a marker, and quite possibly a mediator, of early arterial damage in people who appear healthy.

What makes H5 so dangerous? The answer lies in its molecular cargo. Proteomic analysis revealed that the triglyceride-rich H5 fraction carries a distinct lipoproteome, markedly enriched with apolipoproteins that are not normally prominent passengers on HDL, including apolipoprotein(a), apolipoprotein B, and apolipoprotein C-III. The presence of apolipoprotein(a) is particularly noteworthy because it is the defining protein component of lipoprotein(a), a genetically determined and causally established risk factor for atherosclerotic cardiovascular disease. Apolipoprotein B is the core structural protein of low-density lipoprotein, the classic bad cholesterol, while apolipoprotein C-III is known to impair the breakdown of triglyceride-rich particles. Their enrichment on an HDL particle suggests that H5 is not simply modified HDL but something closer to a molecular chimera, a particle that has acquired atherogenic cargo and, in doing so, lost its protective identity.

Indeed, the study confirmed that H5 suffers from impaired cholesterol efflux, the fundamental housekeeping function that defines healthy HDL. Rather than extracting cholesterol from peripheral tissues and vessel walls, H5 fails at this task, compounding its harm. But the researchers went further, asking what H5 actually does to the endothelial cells that form the inner lining of arteries. Using human umbilical vein endothelial cells in vitro, they found that exposure to H5 triggered a cascade of damaging events: accumulation of reactive oxygen species, the chemically reactive molecules that oxidize and injure cellular components; activation of the DNA damage response; and ultimately cellular senescence, a state in which cells permanently stop dividing but refuse to die, instead secreting a inflammatory cocktail known as the senescence-associated secretory phenotype.

At the heart of this senescence program, the team identified the p53–p21 signaling axis as the central mediator. p53 is the cell’s guardian of the genome, a transcription factor that responds to DNA damage by either halting the cell cycle or initiating cell death. When p53 is activated, it upregulates p21, a cyclin-dependent kinase inhibitor that enforces cell cycle arrest. In endothelial cells exposed to H5, this pathway was switched on, driving the cells into the senescent state. The importance of this axis was confirmed in vivo: in mouse models, H5-induced vascular dysfunction promoted a pro-atherogenic phenotype, and this effect was mediated centrally by the same p53–p21 pathway. The convergence of in vitro and in vivo evidence on a single molecular mechanism lends the findings considerable weight.

The concept of endothelial senescence as a driver of vascular aging has been gaining momentum in the geroscience community. Senescent endothelial cells lose their ability to produce nitric oxide, the signaling molecule that keeps blood vessels dilated and prevents platelets and immune cells from sticking to vessel walls. They also secrete pro-inflammatory cytokines and matrix-degrading enzymes that destabilize atherosclerotic plaques. By showing that a specific lipoprotein subfraction can induce this program through a defined signaling pathway, the study connects lipid biochemistry to the biology of aging in a way that few previous investigations have managed. It also echoes earlier work by some of the same investigators on electronegative low-density lipoprotein, which has been shown to induce mitochondrial dysfunction and premature senescence of vascular cells, suggesting that charge-defined subfractions of both major lipoprotein classes may share senescence-inducing properties.

The translational implications are substantial. If H5 can be reliably measured in clinical laboratories, it could serve as a biomarker for identifying asymptomatic individuals who harbor silent, progressing atherosclerosis despite apparently acceptable conventional lipid profiles. More ambitiously, the identification of the p53–p21 axis as the central mediator raises the possibility of pharmacological intervention, whether by reducing the formation of H5, blocking its interactions with endothelial cells, or modulating the downstream senescence program. The study’s authors argue that their findings validate targeting HDL quality, specifically the H5 subfraction, as a novel therapeutic strategy, a reframing that could finally explain why simply raising HDL cholesterol has failed to improve outcomes in large clinical trials.

Caveats remain, as they always do. The human cohorts were cross-sectional, so the associations between H5 and carotid atherosclerosis, while statistically independent, do not by themselves prove causation in people. The mouse experiments support a causal mechanism, but the extent to which the same pathway operates in human arteries over decades will require longitudinal studies. Still, the work represents a compelling synthesis of epidemiology, proteomics, cell biology, and animal physiology, and it arrives amid renewed interest in lipoprotein(a) as a drug target and in senolytic therapies that clear senescent cells from aging tissues. If future studies confirm that H5 is both a reliable marker and a treatable mediator of vascular aging, the humble HDL particle, long viewed as a one-dimensional hero of cardiovascular health, may turn out to be a far more complicated character, one whose darkest fractions hold the key to keeping arteries young.

Subject of Research: The role of apolipoprotein(a)-rich electronegative HDL subfraction H5 in inducing endothelial senescence and accelerating vascular aging and atherosclerosis

Article Title: Apolipoprotein(a)-rich electronegative HDL accelerates vascular aging and atherosclerosis by inducing endothelial senescence

Article References: Hsu, W.-L., Chung, C.-P., Chung, C., Wei, W.-Y., Chen, T.-Y., Akyol, O., Chiang, H.-H., Chou, M.-C., Kraler, S., Lüscher, T., Tsai, M.-H., & Chen, C.-H. (2026). Apolipoprotein(a)-rich electronegative HDL accelerates vascular aging and atherosclerosis by inducing endothelial senescence. GeroScience. https://doi.org/10.1007/s11357-026-02523-1

Image Credits: AI Generated

DOI: 10.1007/s11357-026-02523-1

Keywords: HDL, H5 subfraction, apolipoprotein(a), endothelial senescence, p53-p21 pathway, atherosclerosis, vascular aging, metabolic syndrome, cholesterol efflux, reactive oxygen species, carotid intima-media thickness, cardiovascular disease

The investigation began with a straightforward question: is alpha-synuclein actually present in atherosclerotic lesions? The team collected carotid plaque specimens from three patients undergoing endarterectomy and subjected them to liquid chromatography–tandem mass spectrometry. Peptides corresponding to alpha-synuclein were detected in every specimen, and western blotting confirmed the finding, revealing an immunoreactive band just above 15 kilodaltons, the expected size of the monomeric protein, along with higher-molecular-weight species that may represent modified or protein-associated forms. This protein-level validation established that the Parkinson’s-associated protein genuinely inhabits the vascular disease environment rather than merely circulating in the bloodstream at large.

To test whether the protein matters functionally, the researchers turned to mice lacking the Snca gene, which encodes alpha-synuclein. Using an adeno-associated virus carrying PCSK9 followed by sixteen weeks of high-cholesterol diet, they induced atherosclerosis in both knockout animals and wild-type littermates. The results were striking: mice without alpha-synuclein developed significantly smaller lesions across the whole aorta and aortic arch, with reduced plaque area, smaller necrotic cores, and diminished lipid deposition at the aortic root. The phenotype appeared in both sexes, and immunofluorescence analysis pinpointed the difference to macrophage-derived foam cells, identified as cells positive for both the macrophage marker CD68 and the lipid dye BODIPY. Lipid-laden smooth muscle cells, by contrast, were not detectably altered, suggesting the protein’s influence is concentrated on the macrophage arm of plaque biology.

Because alpha-synuclein circulates in blood, largely as monomers carried by red blood cells, the team next asked whether extracellular exposure to the protein could actively worsen disease. They injected purified recombinant alpha-synuclein into atherosclerosis-prone Apoe-deficient mice twice weekly for twelve weeks while the animals consumed a high-cholesterol diet. Compared with controls receiving vehicle, the treated mice showed markedly increased lipid deposition in the whole aorta and aortic arch, larger plaques, expanded necrotic cores, and a higher density of macrophage foam cells within lesions. Collagen content, a measure of plaque stability, did not increase proportionally, implying that the additional lipid burden came with reduced lesion stability. In cell culture, adding alpha-synuclein to macrophages exposed to oxidized low-density lipoprotein further amplified neutral lipid accumulation, while uptake of labeled ox-LDL remained unchanged.

The critical clue came from cholesterol efflux assays. When macrophages pre-loaded with fluorescent NBD-cholesterol were treated with alpha-synuclein, their ability to export cholesterol to both high-density lipoprotein and apolipoprotein A-1 acceptors dropped significantly. Curiously, the protein levels of the classical lipid-handling machinery, including the uptake receptors CD36, MSR1, and OLR1 and the transporters ABCA1 and ABCG1, were unaffected. This pointed the investigators away from transcriptional regulation of lipid traffic and toward the autophagy-lysosome system, the intracellular recycling network that, through a process called lipophagy, delivers lipid droplets to lysosomes for hydrolysis and frees cholesterol for export.

A series of complementary experiments converged on a specific defect: the fusion of autophagosomes with lysosomes. Alpha-synuclein-treated macrophages accumulated the autophagy markers LC3B-II and SQSTM1, a signature of blocked degradation rather than enhanced autophagic activity, since chloroquine pre-treatment eliminated the further LC3B-II increase. Confocal microscopy showed reduced colocalization between lipid droplets and lysosomes, between lipid droplets and LC3, and, most tellingly, between LC3-labeled autophagosomes and LAMP1-labeled lysosomes. Transmission electron microscopy revealed fewer autolysosomal structures and enlarged lipid droplets. Finally, a macrophage line stably expressing the tandem RFP-EGFP-LC3 reporter, in which red-only puncta mark completed autolysosomes and yellow puncta mark stalled autophagosomes, showed a clear shift toward yellow puncta after alpha-synuclein treatment. The autophagy conveyor belt, in short, jammed at the fusion step.

Having localized the blockage, the researchers traced it upstream to signaling. The SNARE proteins that physically mediate autophagosome-lysosome fusion, STX17, SNAP29, and VAMP8, were not reduced in abundance, distinguishing macrophages from neurons, where alpha-synuclein overexpression was previously shown to degrade SNAP29. Instead, alpha-synuclein treatment increased phosphorylation of PI3K and AKT, which in turn activated mTOR and its downstream effectors S6K and ULK1 at the inhibitory Ser757 site, while AMPK phosphorylation remained unchanged. Pharmacological intervention confirmed the pathway’s relevance: pretreatment with the PI3K inhibitor LY294002 blunted the mTOR phosphorylation response, and either LY294002 or the mTOR inhibitor rapamycin normalized LC3B-II accumulation and significantly reduced alpha-synuclein-induced lipid droplet buildup. Blocking this axis, in other words, partially rescues the foam cell phenotype.

The remaining question was how extracellular alpha-synuclein gains entry and triggers PI3K signaling. Proteomic comparison of treated and untreated macrophages flagged flotillin-1, or FLOT1, a membrane raft-associated protein previously implicated in alpha-synuclein endocytosis in dopaminergic neurons. Alpha-synuclein treatment increased FLOT1 protein levels, and silencing Flot1 with siRNA markedly reduced the protein’s uptake into macrophages. Immunofluorescence showed intracellular colocalization between alpha-synuclein and FLOT1, and co-immunoprecipitation supported a biochemical association, though the authors note these assays do not establish direct binding. Functionally, Flot1 knockdown abolished the alpha-synuclein-induced phosphorylation of PI3K, prevented the accumulation of LC3B-II, partially reduced SQSTM1 upregulation, restored HDL-mediated cholesterol efflux, and attenuated foam cell formation. Consistent with the in vitro data, atherosclerotic mice injected with alpha-synuclein carried a higher density of FLOT1-positive macrophages in their plaques.

The study’s authors emphasize that endogenous alpha-synuclein expression in macrophages is extremely low, which likely explains why Snca-deficient macrophages showed no intrinsic defect in foaming capacity in vitro. The atheroprotective phenotype of the knockout mice may instead reflect reduced exposure to circulating, extracellular alpha-synuclein, a hypothesis their injection experiments directly support. This reframing matters because it positions alpha-synuclein not merely as a neuronal liability but as a circulating factor whose peripheral levels, already known to be elevated in Parkinson’s patients, could plausibly influence vascular risk. Epidemiological observations lend circumstantial weight: Parkinson’s disease has been associated with a higher prevalence of carotid plaques and an increased risk of ischemic stroke, and alpha-synuclein has been detected in HDL and lipoprotein(a) fractions as well as in cerebrovascular walls and endothelial cell secretions.

The implications reach into therapeutics. The identification of FLOT1 as a candidate entry mediator and of the PI3K-AKT-mTOR axis as the signaling conduit suggests at least two pharmacologically tractable nodes, both already targeted by existing drugs such as rapamycin. The authors caution that inhibitor effects were partial, that SQSTM1 accumulation also reflects transcriptional upregulation possibly tied to inflammatory signaling, and that the colocalization and co-immunoprecipitation data do not prove direct molecular binding. Nonetheless, the convergence of human plaque proteomics, genetic mouse models, and mechanistic cell biology builds a coherent case that extracellular alpha-synuclein impairs macrophage autophagic flux, stalls cholesterol export, and accelerates atherosclerosis. For aging populations, in which declining autophagy and rising vascular disease already converge, the prospect that a single protein links neurodegeneration and arterial pathology offers both a unifying biological insight and a fresh set of intervention points.

Subject of Research: The role of alpha-synuclein in macrophage autophagic dysfunction and atherosclerosis progression

Article Title: α‐Synuclein Promotes Atherosclerosis by Impairing Macrophage Autophagic Flux

Article References: Qin, M., Xiang, X., Guo, X., Wang, S., Chen, J., Jiang, D., Feng, Y., Yu, J., & Mao, L. (2026). α‐Synuclein Promotes Atherosclerosis by Impairing Macrophage Autophagic Flux. Aging Cell, 25(10), Article e70713. https://doi.org/10.1111/acel.70713

Image Credits: AI Generated

DOI: 10.1111/acel.70713

Keywords: alpha-synuclein, atherosclerosis, macrophages, autophagy, foam cells, FLOT1, PI3K-AKT-mTOR, cholesterol efflux, Parkinson's disease, lipophagy, vascular aging, Aging Cell